OppFi Inc., a digital finance platform partnering with banks to serve everyday Americans, will announce its third quarter 2026 financial results on October 28 before the market opens. The company will hold a conference call at 8:30 a.m. ET the same day to discuss its earnings and business outlook. OppFi is known for supporting consumers underserved by traditional finance options and holds a strong customer rating. Investors can access the webcast via the company's website or by phone.
OppFi's upcoming Q3 2026 earnings call is noted here with Pluang's Financials sector data as context. For readers following financial stocks, here is Pluang's market snapshot as of Oct 20, 2026 03:02 WIB: out of 142 priced Financials-sector US stocks, 42 rose and 99 fell today. Notable movers include GEMI at USD 3.23 with a 1-day change of -9.52% and a typical hold time of 15 days, COIN at USD 172.94 down 5.91% with a typical hold time of 79 days and Pluang order activity showing 18% Sell / 82% Buy, and UPST at USD 23.35 down 5.66% with a typical hold time of 39 days.
Dorchester Minerals, L.P. has agreed to acquire mineral and royalty interests covering about 4,300 net royalty acres in three counties within North Dakota's Williston Basin. The deal involves a non-taxable contribution and exchange agreement with an ...
The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...
W. R. Berkley reported mixed Q3 2026 results with earnings per share of $1.17 beating estimates, but revenue fell short at $3.74 billion versus $3.82 billion expected. The company saw premium growth with gross premiums up 3% and net premiums up 1%, s...
GE Aerospace is set to report its Q3 earnings with analysts forecasting a 21.7% rise in earnings per share to $2.02 and nearly 12% revenue growth to about $12.7 billion. Despite consistently beating estimates, the stock has fallen after past reports ...
Silence Therapeutics' stock surged 125.6% to $19.58 following Merck KGaA's agreement to acquire the RNA-interference drug developer for about $1.3 billion in equity value. Merck will pay $20 per share, a 130% premium over the recent closing price. Ot...
